• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
XPE
Click for more information
0.00% 0.2¢

XPED LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
XPE Half Year Financial ReportPRICE SENSITIVE28/02/19
XPE Company Update22/02/19
XPE Appendix 4C - QuarterlyPRICE SENSITIVE31/01/19
XPE Expiry of Listed Options02/01/19
XPE AGM Results of Meeting30/11/18
XPE Chairman's Address to Shareholders30/11/18
XPE Company Update30/11/18
XPE Options Expiry Notice - Waiver20/11/18
XPE Change of Director's Interest Notice08/11/18
XPE Company UpdatePRICE SENSITIVE02/11/18
XPE Appendix 4C - quarterlyPRICE SENSITIVE29/10/18
XPE Notice of Annual General Meeting/Proxy Form25/10/18
XPE Change of Registry Address: Automic P/L - Sydney Office28/09/18
XPE Appendix 4G and Corporate Governance Statement27/09/18
XPE Full Year Statutory Accounts 201827/09/18
XPE Preliminary Final Report - Appendix 4EPRICE SENSITIVE31/08/18
XPE Quarterly Cashflow ReportPRICE SENSITIVE31/07/18
XPE Company UpdatePRICE SENSITIVE31/07/18
XPE Reinstatement to Official QuotationPRICE SENSITIVE28/05/18
XPE Xped Signs Contract to Build IoT Security Device for HeuresyPRICE SENSITIVE28/05/18
XPE Suspension from Official QuotationPRICE SENSITIVE25/05/18
XPE Trading HaltPRICE SENSITIVE23/05/18
XPE Quarterly Cashflow ReportPRICE SENSITIVE30/04/18
XPE Company UpdatePRICE SENSITIVE19/04/18
XPE Appendix 3B Release From Escrow06/04/18
XPE Directors Appointment and Resignation29/03/18
XPE Release of Securities from Escrow14/03/18
XPE Appointment of Joint Company Secretary01/03/18
XPE Half Year Financial ReportPRICE SENSITIVE01/03/18
XPE Quarterly Activities and Cashflow ReportPRICE SENSITIVE31/01/18
XPE Expiry of Listed Options22/01/18
XPE Appendix 3B - exercise of options10/01/18
XPE Xped Enters Cyber-Security SectorPRICE SENSITIVE19/12/17
XPE Options Expiry Notice Waiver18/12/17
XPE Trading HaltPRICE SENSITIVE15/12/17
XPE Xped Expands Use of Digital Coupon TechnologyPRICE SENSITIVE11/12/17
XPE Final Director's Interest Notice - Despain30/11/17
XPE Appendix 3B24/11/17
XPE Result of 2017 Annual General Meeting17/11/17
XPE XPED RECEIVES $2,335,000 R&D TAX REFUNDPRICE SENSITIVE09/11/17
XPE JCT HEALTHCARE SECURES CONTRACTSPRICE SENSITIVE01/11/17
XPE Quarterly Activities and Cashflow ReportPRICE SENSITIVE30/10/17
XPE Appendix 3B and Cleansing Notice23/10/17
XPE ASX Waiver Granted19/10/17
XPE Chairman's and Managing Director's letter to ShareholdersPRICE SENSITIVE17/10/17
XPE Notice of Annual General Meeting/Proxy Form17/10/17
XPE Appendix 4G and Corporate Governance Statement29/09/17
XPE Full Year Statutory Accounts 201729/09/17
XPE Xped announces cost-saving restructurePRICE SENSITIVE25/09/17
XPE Trading HaltPRICE SENSITIVE25/09/17
XPE Change in Substantial Holding22/09/17
XPE Change in Substantial Holding21/09/17
XPE Escrow Release and Expiry of Unlisted Options08/09/17
XPE Company UpdatePRICE SENSITIVE07/09/17
XPE Appointment of Independent Chairman05/09/17
XPE Appendix 3B and Cleansing Notice01/09/17
XPE Preliminary Final Report - Appendix 4EPRICE SENSITIVE01/09/17
XPE Xped to Attend CEDIA 201729/08/17
XPE Xped Sign Agreement with Eastool23/08/17
XPE Completion of $3,000,000 PlacementPRICE SENSITIVE23/08/17
XPE Repayment of Convertible Note23/08/17
XPE Private Placement22/08/17
XPE Trading HaltPRICE SENSITIVE21/08/17
XPE Investor Presentation21/08/17
XPE JCT Healthcare Wins $649,000 TenderPRICE SENSITIVE08/08/17
XPE Appendix 3B - Convertible Note Security07/08/17
XPE Appendix 3B - Convertible Note Conversion04/08/17
XPE CEO letter to Shareholders04/08/17
XPE Quarterly Activities and Caashflow ReportPRICE SENSITIVE01/08/17
XPE Appendix 3B - Bonus Options Shortfall25/07/17
XPE Appendix 3B - Convertible Note Conversion24/07/17
XPE Change of Director's Interest Notice - corrected19/07/17
XPE Change of Director's Interest Notice - Mr Wood19/07/17
XPE Change of Director's Interest Notice - Mr Lekkas19/07/17
XPE Appendix 3B - Bonus Options18/07/17
XPE Company UpdatePRICE SENSITIVE17/07/17
XPE Bonus Options Offer - ShortfallPRICE SENSITIVE14/07/17
XPE Appendix 3B - Part Conversion of Convertible Security10/07/17
XPE Bonus Options Offer Closing10/07/17
XPE 3B and Cleansing Notice - JCT Subsequent Consideration05/07/17
XPE Appendix 3B - Part Conversion of Convertible Security03/07/17
XPE Company UpdatePRICE SENSITIVE03/07/17
XPE Xped sign MoU with JBTPRICE SENSITIVE30/06/17
XPE Bonus Options Offer - Notice to Ineligible Shareholders27/06/17
XPE Share Sale Facility For Unmarketable Parcel Closes27/06/17
XPE Update on Media Intelligence Co. Pty Ltd27/06/17
XPE Appendix 3B - Part Conversion of Convertible Security26/06/17
XPE Bonus Options Offer - Notice To Security Holders20/06/17
XPE Bonus Option Offer - Notice To Option Holder19/06/17
XPE Bonus Options Offer Prospectus and Appendix 3BPRICE SENSITIVE19/06/17
XPE Update on Media Intelligence Co. Pty LtdPRICE SENSITIVE16/06/17
XPE Bonus Options Offer - updated timetable14/06/17
XPE XPED PARTNER WITH COMPAL ELECTRONICSPRICE SENSITIVE13/06/17
XPE Share Consolidation Complete09/06/17
XPE Company UpdatePRICE SENSITIVE02/06/17
XPE Lenze IPark 20 Million OrderPRICE SENSITIVE02/06/17
XPE Update - Consolidation/Split - XPE01/06/17
XPE Share Trading on a Deferred Settlement Basis01/06/17
XPE Appendix 3B01/06/17
XPE Results of Meeting30/05/17
XPE Half Year Financial Report
28/02/19PRICE SENSITIVE
XPE Company Update
22/02/19
XPE Appendix 4C - Quarterly
31/01/19PRICE SENSITIVE
XPE Expiry of Listed Options
02/01/19
XPE AGM Results of Meeting
30/11/18
XPE Chairman's Address to Shareholders
30/11/18
XPE Company Update
30/11/18
XPE Options Expiry Notice - Waiver
20/11/18
XPE Change of Director's Interest Notice
08/11/18
XPE Company Update
02/11/18PRICE SENSITIVE
XPE Appendix 4C - quarterly
29/10/18PRICE SENSITIVE
XPE Notice of Annual General Meeting/Proxy Form
25/10/18
XPE Change of Registry Address: Automic P/L - Sydney Office
28/09/18
XPE Appendix 4G and Corporate Governance Statement
27/09/18
XPE Full Year Statutory Accounts 2018
27/09/18
XPE Preliminary Final Report - Appendix 4E
31/08/18PRICE SENSITIVE
XPE Quarterly Cashflow Report
31/07/18PRICE SENSITIVE
XPE Company Update
31/07/18PRICE SENSITIVE
XPE Reinstatement to Official Quotation
28/05/18PRICE SENSITIVE
XPE Xped Signs Contract to Build IoT Security Device for Heuresy
28/05/18PRICE SENSITIVE
XPE Suspension from Official Quotation
25/05/18PRICE SENSITIVE
XPE Trading Halt
23/05/18PRICE SENSITIVE
XPE Quarterly Cashflow Report
30/04/18PRICE SENSITIVE
XPE Company Update
19/04/18PRICE SENSITIVE
XPE Appendix 3B Release From Escrow
06/04/18
XPE Directors Appointment and Resignation
29/03/18
XPE Release of Securities from Escrow
14/03/18
XPE Appointment of Joint Company Secretary
01/03/18
XPE Half Year Financial Report
01/03/18PRICE SENSITIVE
XPE Quarterly Activities and Cashflow Report
31/01/18PRICE SENSITIVE
XPE Expiry of Listed Options
22/01/18
XPE Appendix 3B - exercise of options
10/01/18
XPE Xped Enters Cyber-Security Sector
19/12/17PRICE SENSITIVE
XPE Options Expiry Notice Waiver
18/12/17
XPE Trading Halt
15/12/17PRICE SENSITIVE
XPE Xped Expands Use of Digital Coupon Technology
11/12/17PRICE SENSITIVE
XPE Final Director's Interest Notice - Despain
30/11/17
XPE Appendix 3B
24/11/17
XPE Result of 2017 Annual General Meeting
17/11/17
XPE XPED RECEIVES $2,335,000 R&D TAX REFUND
09/11/17PRICE SENSITIVE
XPE JCT HEALTHCARE SECURES CONTRACTS
01/11/17PRICE SENSITIVE
XPE Quarterly Activities and Cashflow Report
30/10/17PRICE SENSITIVE
XPE Appendix 3B and Cleansing Notice
23/10/17
XPE ASX Waiver Granted
19/10/17
XPE Chairman's and Managing Director's letter to Shareholders
17/10/17PRICE SENSITIVE
XPE Notice of Annual General Meeting/Proxy Form
17/10/17
XPE Appendix 4G and Corporate Governance Statement
29/09/17
XPE Full Year Statutory Accounts 2017
29/09/17
XPE Xped announces cost-saving restructure
25/09/17PRICE SENSITIVE
XPE Trading Halt
25/09/17PRICE SENSITIVE
XPE Change in Substantial Holding
22/09/17
XPE Change in Substantial Holding
21/09/17
XPE Escrow Release and Expiry of Unlisted Options
08/09/17
XPE Company Update
07/09/17PRICE SENSITIVE
XPE Appointment of Independent Chairman
05/09/17
XPE Appendix 3B and Cleansing Notice
01/09/17
XPE Preliminary Final Report - Appendix 4E
01/09/17PRICE SENSITIVE
XPE Xped to Attend CEDIA 2017
29/08/17
XPE Xped Sign Agreement with Eastool
23/08/17
XPE Completion of $3,000,000 Placement
23/08/17PRICE SENSITIVE
XPE Repayment of Convertible Note
23/08/17
XPE Private Placement
22/08/17
XPE Trading Halt
21/08/17PRICE SENSITIVE
XPE Investor Presentation
21/08/17
XPE JCT Healthcare Wins $649,000 Tender
08/08/17PRICE SENSITIVE
XPE Appendix 3B - Convertible Note Security
07/08/17
XPE Appendix 3B - Convertible Note Conversion
04/08/17
XPE CEO letter to Shareholders
04/08/17
XPE Quarterly Activities and Caashflow Report
01/08/17PRICE SENSITIVE
XPE Appendix 3B - Bonus Options Shortfall
25/07/17
XPE Appendix 3B - Convertible Note Conversion
24/07/17
XPE Change of Director's Interest Notice - corrected
19/07/17
XPE Change of Director's Interest Notice - Mr Wood
19/07/17
XPE Change of Director's Interest Notice - Mr Lekkas
19/07/17
XPE Appendix 3B - Bonus Options
18/07/17
XPE Company Update
17/07/17PRICE SENSITIVE
XPE Bonus Options Offer - Shortfall
14/07/17PRICE SENSITIVE
XPE Appendix 3B - Part Conversion of Convertible Security
10/07/17
XPE Bonus Options Offer Closing
10/07/17
XPE 3B and Cleansing Notice - JCT Subsequent Consideration
05/07/17
XPE Appendix 3B - Part Conversion of Convertible Security
03/07/17
XPE Company Update
03/07/17PRICE SENSITIVE
XPE Xped sign MoU with JBT
30/06/17PRICE SENSITIVE
XPE Bonus Options Offer - Notice to Ineligible Shareholders
27/06/17
XPE Share Sale Facility For Unmarketable Parcel Closes
27/06/17
XPE Update on Media Intelligence Co. Pty Ltd
27/06/17
XPE Appendix 3B - Part Conversion of Convertible Security
26/06/17
XPE Bonus Options Offer - Notice To Security Holders
20/06/17
XPE Bonus Option Offer - Notice To Option Holder
19/06/17
XPE Bonus Options Offer Prospectus and Appendix 3B
19/06/17PRICE SENSITIVE
XPE Update on Media Intelligence Co. Pty Ltd
16/06/17PRICE SENSITIVE
XPE Bonus Options Offer - updated timetable
14/06/17
XPE XPED PARTNER WITH COMPAL ELECTRONICS
13/06/17PRICE SENSITIVE
XPE Share Consolidation Complete
09/06/17
XPE Company Update
02/06/17PRICE SENSITIVE
XPE Lenze IPark 20 Million Order
02/06/17PRICE SENSITIVE
XPE Update - Consolidation/Split - XPE
01/06/17
XPE Share Trading on a Deferred Settlement Basis
01/06/17
XPE Appendix 3B
01/06/17
XPE Results of Meeting
30/05/17
refresh Created with Sketch. REFRESH
 

Top Stories

HotCopper Highlights: Your most watched stocks for Week 46, 2024

What you - HotCopper users - were most interested in viewing and discussing this week (Week 46 of the year!)
Banshee's historic trenches prove rich in antimony and gold for GDM Great Divide Mining Ltd has found high-grade antimony and gold through geochemical sampling at its Banshee prospect in Queensland
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch CuFe Ltd (ASX:CUF) has decided not to wait around for Northern Star's Crossroads mine to get up and running, selling its $4M royalty right.
InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.